Secondary economic analysis of an RCT in 746 adults with subjective cognitive decline or MCI: APPLE-Tree plus usual care was not cost-effective on QALYs over 2 years (difference −0.010; 12% probability at £30 000), but 96% probable per 1-point cognition gain.
Secondary analysisn = 746
Demnitz-King et al. Cost utility and cost-effectiveness of the APPLE-Tree programme: Active Prevention in People at risk of dementia through Lifestyle, bEhaviour change and Technology to build REsiliEnce: economic evaluation embedded within a randomised controlled trial